20 articles
Researchers discover how cancer cells use metabolic enzyme PHGDH to evade immune detection, opening new combination therapy approaches.
A muscle enzyme that declines in heart attack patients may hold the key to preserving cardiac function after MI.
Breakthrough study shows one epigenetic factor can transform cardiac fibroblasts into heart muscle cells, improving function after myocardial infarction.
A longevity-linked protein blocks two key mechanisms of doxorubicin heart damage, offering a potential cardioprotective strategy for cancer patients.
New research reveals how GRK2 protein clumping damages brain cells and identifies potential therapeutic targets to slow cognitive decline.
New oral drug MK-0616 matches injectable PCSK9 inhibitors for lowering LDL cholesterol while offering patient-friendly pill form.
Breakthrough discovery of PAK1 kinase activators shows promise for treating cardiac hypertrophy and heart failure through targeted enzyme enhancement.
Scientists uncover how faulty glycogen-priming proteins cause progressive cardiomyopathy, pointing toward gene therapy and autophagy as future treatments.
A new molecular target — the E3 ubiquitin ligase Hrd1 — may prevent heart damage after blood flow is restored following a heart attack.
A proteomics screen of 2,920 plasma proteins identifies a 17-protein score that lifts heart failure prediction accuracy to 0.833 C-index in type 2 diabetes patients.
A protein linked to cardiovascular protection predicts mitral valve deterioration and heart failure risk after STEMI, opening a new prognostic window.
Advanced cardiac troponin test demonstrates improved sensitivity for detecting heart attacks in emergency settings.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
Scientists discover how an unusual gene fusion in melanoma still drives cancer growth and responds to targeted treatment.
New analysis shows ANGPTL3 inhibitors reduce cholesterol 50% vs 18% for PCSK9 drugs in patients with severe genetic hypercholesterolemia.
Cas13-based RNA editing shows promise for treating hereditary hypertrophic cardiomyopathy by correcting disease-causing mutations at the RNA level.
Scientists identify GSDME as a master switch driving abdominal aortic aneurysms through vascular aging, opening new treatment paths.
Dr. Jamnadas explains advanced testing and root cause analysis for coronary calcium, including insulin resistance and leaky gut connections.
